SCHEMBL4774922

SCHEMBL4774922

CS(=O)(=O)N(Cc1cccc(Cl)c1Cl)c1ccc(N(C=O)CC2CNCCO2)cc1

nearest known ligand 0.41

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
SLC6A4 P31645 14/20 0.41
SLC6A2 P23975 12/20 0.41
SLC6A3 Q01959 10/20 0.41
CYP2D6 P10635 7/20 0.41
KCNH2 Q12809 3/20 0.38
CYP3A4 P08684 2/20 0.38
RECQL P46063 1/20 0.37
CYP1A2 P05177 1/20 0.35
CYP2C9 P11712 1/20 0.35
CYP2C19 P33261 1/20 0.35
ALDH1A1 P00352 2/20 0.34
POLB P06746 1/20 0.34
REN P00797 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4776553 0.86 RECQL (0.49) SLC6A4SLC6A2SLC6A3CYP2D6RECQL
SCHEMBL4776757 0.84 SLC6A4 (0.42) SLC6A4SLC6A2SLC6A3CYP2D6KCNH2
SCHEMBL4777305 0.83 SLC6A4 (0.45) SLC6A4SLC6A2SLC6A3CYP2D6KCNH2
SCHEMBL5571819 0.81 SLC6A4 (0.42) SLC6A4SLC6A2SLC6A3CYP2D6KCNH2
SCHEMBL4777347 0.76 NR1H4 (0.39) SLC6A4SLC6A2SLC6A3CYP2D6KCNH2
SCHEMBL4774929 0.76 SLC6A4 (0.42) SLC6A4SLC6A2SLC6A3CYP2D6KCNH2
SCHEMBL4768070 0.74 SLC6A4 (0.44) SLC6A4SLC6A2SLC6A3CYP2D6KCNH2
SCHEMBL4775082 0.74 GHSR (0.36) SLC6A4SLC6A2SLC6A3CYP2D6KCNH2
SCHEMBL4776590 0.74 GAA (0.42) RECQLALDH1A1POLB
SCHEMBL4775060 0.73 GAA (0.39) RECQLALDH1A1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1942888-A2 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS Cytokinetics, Inc. (US) 2008-07-16 EP claimed
US-20070135435-A1 Certain chemical entities, compositions, and methods CYTOKINETICS, INCORPORATED 2007-06-14 US claimed
WO-2007056078-A2 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS CYTOKINETICS, INC. (US) 2007-05-18 WO claimed
EP-1942888-A2 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS Cytokinetics, Inc. (US) 2008-07-16 EP disclosed
US-20070135435-A1 Certain chemical entities, compositions, and methods CYTOKINETICS, INCORPORATED 2007-06-14 US disclosed
WO-2007056078-A2 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS CYTOKINETICS, INC. (US) 2007-05-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070135435-A1 Certain chemical entities, compositions, and methods KIF5B, KIF2C, PLK1 SLC6A4 3990/4885SLC6A2 3818/4885SLC6A3 3419/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.